人工智慧（AI）藥物研發市場的分析與預測（至2035年）：按類型、產品、服務、技術、組件、應用、流程、最終用戶和解決方案

全球人工智慧（AI）藥物研發市場預計將從2025年的39億美元成長到2035年的208億美元，CAGR為18.1%。在數位轉型措施不斷推進和生物醫學資料集不斷擴展的推動下，人工智慧已成為全球製藥研發領域的策略性投資。據美國食品藥物管理局（FDA）表示，透過先進的建模和資料分析技術，人工智慧在藥物研發和監管科學領域的應用持續成長。美國國立衛生研究院（NIH）已透過多個計畫大幅增加了對人工智慧驅動的生物醫學研究的資助，而產業財務報告顯示，全球製藥公司正持續增加研發支出，年投入超過2900億美元。市場評估預測，未來十年，在人工智慧開發商與製藥公司之間合作加速的推動下，該市場將保持兩位數的年成長率。

機器學習已成為主流技術，它能夠利用結構化生物資料集進行預測分析、分子性質評估和候選藥物優先排序。深度學習透過提高計算精度，增強了蛋白質結構預測、從頭分子生成和複雜生化相互作用建模的能力。自然語言處理技術能夠從專利、學術論文、電子健康記錄和臨床文獻中提取有價值的科學見解，促進知識發現和假設生成。電腦視覺透過影像識別演算法支援自動化顯微鏡、細胞成像、病理分析和表現型篩檢。運算基礎設施的持續改進、基於雲端的人工智慧平台以及生物醫學資料集的不斷擴展，預計將推動藥物研發領域技術的持續應用。

標靶辨識是一項關鍵應用領域，它透過分析基因組學、蛋白質組學和分子水平資料集來識別疾病相關的生物標記。人工智慧驅動的分子篩檢能夠加速虛擬篩檢並預測化合物相互作用，同時減少實驗室檢測需求。先導化合物最佳化利用預測演算法在實驗室檢驗前提高藥物的療效、毒性、藥物動力學和分子穩定性。在臨床前試驗中，人工智慧模型可以模擬生物反應，減少實驗迭代次數並改善候選化合物的選擇。人工智慧在臨床試驗中的應用能夠增強受試者招募、最佳化方案、預測終點事件並實現即時監測。隨著精準醫療和資料驅動藥物研發需求的不斷成長，人工智慧在藥物發現的各個階段的應用也持續擴展。

區域概覽

北美之所以能保持主導地位，是因為這裡匯集了許多全球製藥公司、生物技術創新者、領先的研究機構和人工智慧技術供應商。該地區受益於成熟的雲端運算基礎設施、龐大的基因組資料庫、創業投資管道以及強大的產學合作。政府支持的生物醫學研究計畫和創新促進政策推動人工智慧融入藥物研發流程。大型製藥企業不斷拓展人工智慧合作，以提高研發效率；完善的法律規範和高額的醫療保健支出也為人工智慧驅動的藥物研發平台在美國和加拿大的商業化提供了支援。

在亞太地區，人工智慧的應用正隨著製藥產能的提升、政府主導的生物技術舉措以及對人工智慧基礎設施投資的增加而不斷擴展。中國、日本、韓國、新加坡和印度等國家加強其計算生物學能力，並在大學和製藥公司之間建立以人工智慧為重點的研究夥伴關係。臨床研究活動的活性化、醫療保健資料集的擴展以及創業投資投資的成長，都在支持這項技術的商業化。本土生物技術新創公司正積極與跨國製藥公司合作，以加速藥物研發計畫；支持數位醫療持續現代化和創新的政策，全部區域創造長期的市場機會。

主要趨勢和促進因素

加強科技公司與製藥公司之間的合作：

人工智慧技術公司與製藥公司之間的合作顯著增加。這些合作目的是利用人工智慧技術來改善藥物研發流程。透過將技術創新與製藥知識相結合，這些合作推動新藥候選物的發現和臨床試驗的最佳化。隨著雙方都認知到共用專業知識和資源的互惠互利，預計這一趨勢將持續下去。

人工智慧驅動的研發推動製藥業的變革。

降低藥物研發成本和縮短研發週期的壓力日益增大，推動了人工智慧驅動的藥物發現平台的廣泛應用。製藥公司正擴大利用預測分析、虛擬篩檢和計算建模來改進候選化合物的選擇、最大限度地減少實驗室失敗並最佳化資源分配。精準醫療投入的增加、生物醫學資料庫的擴展以及高效能運算的持續進步，進一步增強了將人工智慧融入整個藥物研發流程的商業可行性。

目錄

第1章 執行摘要

第2章 市場亮點

第3章 市場動態

• 宏觀經濟分析
• 市場趨勢
• 市場促進因素
• 市場機會
• 市場限制因素
• 年複合成長率分析
• 影響分析
• 新興市場
• 技術藍圖
• 戰略框架

第4章 細分市場分析

• 市場規模及預測：依類型
  • 機器學習
  • 深度學習
  • 自然語言處理
  • 其他
• 市場規模及預測：依產品分類
  • 軟體
  • 平台
  • 工具
  • 其他
• 市場規模及預測：依服務分類
  • 諮詢
  • 整合與實施
  • 支援與維護
  • 其他
• 市場規模及預測：依技術分類
  • 雲端
  • 現場
  • 混合
  • 其他
• 市場規模及預測：依組件分類
  • 人工智慧演算法
  • 資料庫
  • API
  • 其他
• 市場規模及預測：依應用領域分類
  • 目標識別
  • 分子篩檢
  • 先導化合物最佳化
  • 臨床前試驗
  • 臨床試驗
  • 其他
• 市場規模及預測：依製程分類
  • 藥物發現
  • 藥物篩檢
  • 現有藥物的再利用
  • 其他
• 市場規模及預測：依最終用戶分類
  • 製藥公司
  • 生技公司
  • 研究機構
  • 受託研究機構
  • 其他
• 市場規模及預測：依解決方案分類
  • 客製化解決方案
  • 現成的解決方案
  • 其他

第5章 區域分析

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 其他拉丁美洲國家
• 亞太地區
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲
  • 台灣
  • 其他亞太國家
• 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 其他歐洲國家
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 撒哈拉以南非洲
  • 其他中東和非洲國家

第6章 市場策略

• 供需差距分析
• 貿易和物流限制
• 價格、成本和利潤率趨勢
• 市場滲透率
• 消費者分析
• 監管概述

第7章 競爭訊息

• 市場定位
• 市場占有率
• 競爭基準
• 主要公司的策略

第8章 公司簡介

• IBM
• Google
• Microsoft
• BenevolentAI
• Insilico Medicine
• Exscientia
• Atomwise
• Cyclica
• Schrodinger
• Recursion Pharmaceuticals
• XtalPi
• BioSymetrics
• Deep Genomics
• Numerate
• Cloud Pharmaceuticals
• PathAI
• GNS Healthcare
• Verge Genomics
• Owkin
• Aria Pharmaceuticals

第9章 關於我們

The global Artificial Intelligence for Drug Discovery Market is projected to grow from $3.9 billion in 2025 to $20.8 billion by 2035, at a compound annual growth rate (CAGR) of 18.1%. Artificial intelligence has become a strategic investment area across global pharmaceutical research, supported by increasing digital transformation initiatives and expanding biomedical datasets. According to the U.S. Food and Drug Administration, AI adoption in drug development and regulatory science continues to increase through advanced modeling and data analytics initiatives. The National Institutes of Health has significantly expanded AI-enabled biomedical research funding under multiple programs, while global pharmaceutical companies continue increasing R&D expenditures exceeding USD 290 billion annually according to industry financial reports. Market assessments consistently project double-digit annual growth through the next decade, driven by accelerating partnerships between AI developers and pharmaceutical organizations.

Machine learning dominates technology adoption by enabling predictive analytics, molecular property estimation, and drug candidate prioritization using structured biological datasets. Deep learning strengthens protein structure prediction, de novo molecule generation, and complex biochemical interaction modeling with improved computational accuracy. Natural language processing extracts valuable scientific insights from patents, publications, electronic health records, and clinical literature to enhance knowledge discovery and hypothesis generation. Computer vision supports automated microscopy, cellular imaging, pathology analysis, and phenotypic screening through image recognition algorithms. Continuous improvements in computational infrastructure, cloud-based AI platforms, and expanding biomedical datasets are expected to sustain technology adoption across pharmaceutical R&D.

Target identification represents a critical application by analyzing genomic, proteomic, and molecular datasets to identify disease-associated biomarkers. AI-powered molecule screening accelerates virtual screening and predicts compound interactions while reducing laboratory testing requirements. Lead optimization utilizes predictive algorithms to improve efficacy, toxicity, pharmacokinetics, and molecular stability before laboratory validation. During preclinical testing, AI models simulate biological responses, reducing experimental iterations and improving candidate selection. Clinical trial applications enhance patient recruitment, protocol optimization, endpoint prediction, and real-time monitoring. Increasing demand for precision medicine and data-driven pharmaceutical development continues to expand AI deployment across every stage of drug discovery.

Geographical Overview

North America maintains a leading position through its concentration of global pharmaceutical companies, biotechnology innovators, advanced research institutions, and AI technology providers. The region benefits from mature cloud computing infrastructure, extensive genomic databases, venture capital availability, and strong collaboration between academia and industry. Government-supported biomedical research programs and favorable innovation policies encourage AI integration into drug discovery workflows. Major pharmaceutical organizations continue expanding AI partnerships to improve research productivity, while established regulatory frameworks and high healthcare expenditures support commercialization of AI-driven drug discovery platforms across the United States and Canada.

Asia-Pacific demonstrates expanding adoption through increasing pharmaceutical manufacturing capacity, government-backed biotechnology initiatives, and growing investments in artificial intelligence infrastructure. Countries including China, Japan, South Korea, Singapore, and India are strengthening computational biology capabilities and establishing AI-focused research collaborations between universities and pharmaceutical companies. Rising clinical research activities, expanding healthcare datasets, and increasing venture capital investments support technology commercialization. Local biotechnology startups are actively partnering with multinational pharmaceutical companies to accelerate drug discovery programs, while continued digital healthcare modernization and supportive innovation policies create favorable long-term market opportunities across the region.

Key Trends and Drivers

Increased Collaboration Between Tech and Pharma Companies:

There is a notable increase in partnerships between technology firms specializing in AI and pharmaceutical companies. These collaborations aim to leverage AI expertise to enhance drug discovery processes. By combining technological innovation with pharmaceutical knowledge, these partnerships are driving advancements in identifying novel drug candidates and optimizing clinical trials. This trend is expected to continue as both sectors recognize the mutual benefits of shared expertise and resources.

AI-Powered R&D Driving Pharmaceutical Transformation:

Growing pressure to reduce drug development costs and shorten research timelines is driving widespread adoption of AI-powered drug discovery platforms. Pharmaceutical companies increasingly leverage predictive analytics, virtual screening, and computational modeling to improve candidate selection, minimize laboratory failures, and optimize resource allocation. Rising investments in precision medicine, expanding biomedical databases, and continuous advances in high-performance computing further strengthen the business case for integrating AI throughout pharmaceutical research and development.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Component
• 2.6 Key Market Highlights by Application
• 2.7 Key Market Highlights by Process
• 2.8 Key Market Highlights by End User
• 2.9 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Machine Learning
  • 4.1.2 Deep Learning
  • 4.1.3 Natural Language Processing
  • 4.1.4 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Software
  • 4.2.2 Platforms
  • 4.2.3 Tools
  • 4.2.4 Others
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Consulting
  • 4.3.2 Integration and Implementation
  • 4.3.3 Support and Maintenance
  • 4.3.4 Others
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Cloud-based
  • 4.4.2 On-premise
  • 4.4.3 Hybrid
  • 4.4.4 Others
• 4.5 Market Size & Forecast by Component (2020-2035)
  • 4.5.1 AI Algorithms
  • 4.5.2 Databases
  • 4.5.3 APIs
  • 4.5.4 Others
• 4.6 Market Size & Forecast by Application (2020-2035)
  • 4.6.1 Target Identification
  • 4.6.2 Molecule Screening
  • 4.6.3 Lead Optimization
  • 4.6.4 Preclinical Testing
  • 4.6.5 Clinical Trials
  • 4.6.6 Others
• 4.7 Market Size & Forecast by Process (2020-2035)
  • 4.7.1 Drug Design
  • 4.7.2 Drug Screening
  • 4.7.3 Drug Repurposing
  • 4.7.4 Others
• 4.8 Market Size & Forecast by End User (2020-2035)
  • 4.8.1 Pharmaceutical Companies
  • 4.8.2 Biotechnology Companies
  • 4.8.3 Research Institutes
  • 4.8.4 Contract Research Organizations
  • 4.8.5 Others
• 4.9 Market Size & Forecast by Solutions (2020-2035)
  • 4.9.1 Custom Solutions
  • 4.9.2 Off-the-shelf Solutions
  • 4.9.3 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Component
    • 5.2.1.6 Application
    • 5.2.1.7 Process
    • 5.2.1.8 End User
    • 5.2.1.9 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Component
    • 5.2.2.6 Application
    • 5.2.2.7 Process
    • 5.2.2.8 End User
    • 5.2.2.9 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Component
    • 5.2.3.6 Application
    • 5.2.3.7 Process
    • 5.2.3.8 End User
    • 5.2.3.9 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Component
    • 5.3.1.6 Application
    • 5.3.1.7 Process
    • 5.3.1.8 End User
    • 5.3.1.9 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Component
    • 5.3.2.6 Application
    • 5.3.2.7 Process
    • 5.3.2.8 End User
    • 5.3.2.9 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Component
    • 5.3.3.6 Application
    • 5.3.3.7 Process
    • 5.3.3.8 End User
    • 5.3.3.9 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Component
    • 5.4.1.6 Application
    • 5.4.1.7 Process
    • 5.4.1.8 End User
    • 5.4.1.9 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Component
    • 5.4.2.6 Application
    • 5.4.2.7 Process
    • 5.4.2.8 End User
    • 5.4.2.9 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Component
    • 5.4.3.6 Application
    • 5.4.3.7 Process
    • 5.4.3.8 End User
    • 5.4.3.9 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Component
    • 5.4.4.6 Application
    • 5.4.4.7 Process
    • 5.4.4.8 End User
    • 5.4.4.9 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Component
    • 5.4.5.6 Application
    • 5.4.5.7 Process
    • 5.4.5.8 End User
    • 5.4.5.9 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Component
    • 5.4.6.6 Application
    • 5.4.6.7 Process
    • 5.4.6.8 End User
    • 5.4.6.9 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Component
    • 5.4.7.6 Application
    • 5.4.7.7 Process
    • 5.4.7.8 End User
    • 5.4.7.9 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Component
    • 5.5.1.6 Application
    • 5.5.1.7 Process
    • 5.5.1.8 End User
    • 5.5.1.9 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Component
    • 5.5.2.6 Application
    • 5.5.2.7 Process
    • 5.5.2.8 End User
    • 5.5.2.9 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Component
    • 5.5.3.6 Application
    • 5.5.3.7 Process
    • 5.5.3.8 End User
    • 5.5.3.9 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Component
    • 5.5.4.6 Application
    • 5.5.4.7 Process
    • 5.5.4.8 End User
    • 5.5.4.9 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Component
    • 5.5.5.6 Application
    • 5.5.5.7 Process
    • 5.5.5.8 End User
    • 5.5.5.9 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Component
    • 5.5.6.6 Application
    • 5.5.6.7 Process
    • 5.5.6.8 End User
    • 5.5.6.9 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Component
    • 5.6.1.6 Application
    • 5.6.1.7 Process
    • 5.6.1.8 End User
    • 5.6.1.9 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Component
    • 5.6.2.6 Application
    • 5.6.2.7 Process
    • 5.6.2.8 End User
    • 5.6.2.9 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Component
    • 5.6.3.6 Application
    • 5.6.3.7 Process
    • 5.6.3.8 End User
    • 5.6.3.9 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Component
    • 5.6.4.6 Application
    • 5.6.4.7 Process
    • 5.6.4.8 End User
    • 5.6.4.9 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Component
    • 5.6.5.6 Application
    • 5.6.5.7 Process
    • 5.6.5.8 End User
    • 5.6.5.9 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 IBM
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Google
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Microsoft
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 BenevolentAI
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Insilico Medicine
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Exscientia
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Atomwise
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Cyclica
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Schrodinger
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Recursion Pharmaceuticals
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 XtalPi
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 BioSymetrics
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Deep Genomics
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Numerate
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Cloud Pharmaceuticals
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 PathAI
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 GNS Healthcare
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Verge Genomics
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Owkin
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Aria Pharmaceuticals
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us